Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Abstract

First‐line options for the treatment of dry eye disease (DED) rely on artificial tears (ATs), among which cationic emulsion (CE)‐based ATs have been developed in order to mimic the healthy tear film for an improved restoration of the ocular surface homeostasis. In this review, we describe the outcomes reported in several studies, assessing the mode of action, ocular tolerance and clinical performance of a CE‐based AT. Pilot studies have revealed that CE‐based ATs can increase the volume and stability of the tear film while limiting its evaporation rate. Larger studies have demonstrated that CE‐based ATs play a significant role in the improvement of both objective and subjective DED parameters, including superior efficacy on DED symptoms compared to several other available AT formulation types. Concomitantly, CE‐based ATs have been shown to help patients to prevent or recover from corneal defects associated with refractive surgery. These positive outcomes on ocular surface epithelia are likely due to the combination of unique rheological behaviour and intrinsic anti‐inflammatory properties. Based on all clinical findings, CE‐based ATs represent a valuable treatment option for patients with various etiologies of DED including evaporative forms and would deserve evaluation of benefits in other surgical intervention types triggering DED.